DSpace Repositorium (Manakin basiert)

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Zur Kurzanzeige

dc.contributor.author Kukkle, Prashanth Lingappa
dc.contributor.author Garg, Divyani
dc.contributor.author Merello, Marcelo
dc.date.accessioned 2024-01-04T14:12:35Z
dc.date.available 2024-01-04T14:12:35Z
dc.date.issued 2023-06-14
dc.identifier.citation Kukkle PL, Garg D, Merello M. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review. Mov Disord Clin Pract. 2023 Jun 26;10(9):1253-1267. doi: 10.1002/mdc3.13810 es_ES
dc.identifier.uri https://doi.org/10.1002/mdc3.13810
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/953
dc.description.abstract Background: Continuous subcutaneous apomorphine infusion (CSAI) is one of the advanced therapies for Parkinson's disease (PD). Methods: A systematic review of all published articles in English on CSAI for PD till January 30, 2022 was conducted. Results: A total of 82 articles met the search criteria. Publications included retrospective or prospective open-label observational studies, with a limited number of randomized control trials (RCT). Publications were highly heterogeneous and focused on different aspects of CSAI and included clinical audits, effects on cognition/behavior, axial symptoms, nocturnal issues, adverse events/reasons for discontinuation and comparison with other continuous dopaminergic therapies. CSAI was used in patients who presented severe motor fluctuations not resolved by oral therapy, poor candidates for deep brain stimulation (DBS) due to cognitive/behavioral issues or in those with DBS weaning effect. Recent studies have also shown that CSAI was useful for nocturnal usage in advanced PD, in addition to daytime utilization. Adverse effects were common and include skin lesions, sedation and nausea. Pump management difficulties and patient decisions were common reasons for therapy dropout, predominantly during the initial stages of the CSAI. Conclusion: There is consistent agreement on the benefits of CSAI in reducing OFF periods and improving ON periods without troublesome dyskinesia and specific motor and non-motor symptoms. Although there is a paucity of RCTs, current data from almost 30 years of use suggests CSAI to be beneficial in advanced cases of PD. es_ES
dc.language.iso eng es_ES
dc.publisher Wiley es_ES
dc.subject Parkinson Disease es_ES
dc.subject Enfermedad de Parkinson es_ES
dc.subject Apomorphine es_ES
dc.subject Apomorfina es_ES
dc.title Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.description.fil Fil: Merello, Marcelo. Fleni. Departamento de Neurología. Servicio de Movimientos Anormales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.
dc.relation.ispartofVOLUME 10
dc.relation.ispartofNUMBER 9
dc.relation.ispartofPAGINATION 1253-1267
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Hoboken
dc.relation.ispartofTITLE Movement disorders clinical practice
dc.relation.ispartofISSN 2330-1619
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik